Real-world clinical outcomes of biologic-naive non-complicated Crohn's disease patients treated with vedolizumab: Results from the EVOLVE study

被引：0
|
作者：
Yarur, A. [1 ]
Mantzaris, G. J. [2 ]
Kopylov, U. [3 ]
Bassel, M. [4 ]
Brett, N. [4 ]
Kim, H. [5 ]
Lopez, C. [6 ]
Saha, S. [7 ]
Kifnidi, C. [8 ]
Agboton, C. [9 ]
Adsul, S. [9 ]
Demuth, D. [10 ]
Luo, M. [11 ]
Wang, S. [11 ]
Bressler, B. [12 ]
机构：
[1] Med Coll Wisconsin, Gastroenterol, Milwaukee, WI 53226 USA
[2] Evangelismos Med Ctr, Gastroenterol, Athens, Greece
[3] Sheba Med Ctr, Gastroenterol, Tel Aviv, Israel
[4] Evidera, Real World Evidence, Montreal, PQ, Canada
[5] Evidera, Data Analyt, Waltham, MA USA
[6] Takeda Pharmaceut USA Inc, Med Affairs, Deerfield, IL USA
[7] Takeda Canada Inc, Med Affairs, Oakville, ON, Canada
[8] Takeda Hellas SA, Med Affairs, Athens, Greece
[9] Takeda Pharmaceut Int AG, Global Med Affairs, Zurich, Switzerland
[10] Takeda Pharmaceut Int, Evidence Generat & Publicat, Singapore, Singapore
[11] Takeda Pharmaceut Int, Global Outcomes Res, Boston, MA USA
[12] St Pauls Hosp, Gastroenterol, Vancouver, BC, Canada
来源：
JOURNAL OF CROHNS & COLITIS | 2020年 / 14卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P387
引用
收藏
页码：S360 / S361
页数：2
相关论文
共 50 条
  • [41] EARLY USE OF VEDOLIZUMAB VERSUS INFLIXIMAB IN BIOLOGIC-NAIVE PATIENTS WITH ULCERATIVE COLITIS: A REAL-WORLD ANALYSIS OF HEALTHCARE UTILIZATION
    Patel, Haridarshan
    Khalid, Javaria M.
    Shah, Surbhi
    Shah, Rikisha
    Berger, Ariel
    GASTROENTEROLOGY, 2018, 154 (06) : S371 - S371
  • [42] Adalimumab therapy for psoriasis in real-world practice: efficacy, safety and results in biologic-naive vs. non-naive patients
    van Lumig, P. P. M.
    van de Kerkhof, P. C. M.
    Boezeman, J. B. M.
    Driessen, R. J. B.
    de Jong, E. M. G. J.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2013, 27 (05) : 593 - 600
  • [43] Comparative real-world effectiveness and persistence of vedolizumab versus anti-TNF therapy in biologic-naive patients with Crohn's Disease with Propensity Score adjustment: Maintenance phase results at week-52 from the prospective VEDOIBD study
    Di Giuseppe, R.
    Plachta-Danielzik, S.
    Bokemeyer, B.
    Efken, P.
    Mohl, W.
    Hoffstadt, M.
    Krause, T.
    Schweitzer, A.
    Schnoy, E.
    Atreya, R.
    Teich, N.
    Trentmann, L.
    Ehehalt, R.
    Franzenburg, S.
    Hartmann, P.
    Schreiber, S.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I120 - I121
  • [44] Utilization Trends and Impact of Secukinumab Treatment on Clinical Outcomes in Biologic-Naive Patients with Psoriasis in a US Real-World Setting
    Bruce Strober
    Dhaval Patil
    Robert R. McLean
    Melissa Moore-Clingenpeel
    Ning Guo
    Eugenia Levi
    Mark Lebwohl
    Dermatology and Therapy, 2022, 12 : 1351 - 1365
  • [45] Utilization Trends and Impact of Secukinumab Treatment on Clinical Outcomes in Biologic-Naive Patients with Psoriasis in a US Real-World Setting
    Strober, Bruce
    Patil, Dhaval
    McLean, Robert R.
    Moore-Clingenpeel, Melissa
    Guo, Ning
    Levi, Eugenia
    Lebwohl, Mark
    DERMATOLOGY AND THERAPY, 2022, 12 (06) : 1351 - 1365
  • [46] Characteristics of Patients With Crohn's Disease Initiating Vedolizumab Therapy in Real-World Clinical Practice
    Khalid, Javaria M.
    Reynolds, Matthew
    Alam, Naufil
    Don, O'Hara
    Smyth, Michael D. L.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2015, 110 : S773 - S774
  • [47] Early ustekinumab use improves clinical outcomes in biologic-naive Crohn's Disease patients: A retrospective multicenter cohort study in Taiwan
    Chang, Y. C.
    Chuang, C. H.
    Huang, T. Y.
    Chung, C. S.
    Kuo, C. J.
    Pan, Y. B.
    Sheng, W. J.
    Lin, S. H.
    Le, P. H.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i1473 - i1475
  • [48] Early Ustekinumab Use Improves Clinical Outcomes in Biologic-Naive Crohn's Disease Patients: A Retrospective Multicenter Cohort Study in Taiwan
    Chang, Yen-Cheng
    Chuang, Chiao-Hsiung
    Huang, Tien-Yu
    Chung, Chen-Shuan
    Kuo, Chia-Jung
    Pan, Yu-Bin
    Le, Puo-Hsien
    BIOMEDICINES, 2025, 13 (02)
  • [49] Effectiveness and safety of tocilizumab in monotherapy in biologic-naive and non-naive patients with rheumatoid arthritis in a real-world setting
    Marsal Barril, Sara
    Auxiliadora Martin-Martinez, Ma
    Javier Blanco-Garcia, Francisco
    Fernandez-Nebro, Antonio
    Garcia de Vicuna, Rosario
    Tornero-Molina, Jesus
    Sanchez-Alonso, Fernando
    Novella-Navarro, Marta
    Escudero-Contreras, Alejandro
    Jose Alegre-Sancho, Juan
    Urruticoechea-Arana, Ana
    Sagrario Bustabad-Reyes, Maria
    Trenor-Larraz, Pilar
    Perez-Sandoval, Trinidad
    Isabel Tevar-Sanchez, Maria
    Sanchez-Costa, Jesus T.
    Raya-Alvarez, Enrique
    REUMATOLOGIA CLINICA, 2022, 18 (10): : 567 - 573
  • [50] Early use of vedolizumab vs. infliximab in biologic-naive patients with ulcerative colitis: A real-world analysis of healthcare utilisation
    Patel, H.
    Khalid, J. M.
    Shah, S.
    Shah, R.
    Berger, A.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S385 - S386
12345